Elevation of β-galactoside α2,6-sialyltransferase 1 in a fructoseresponsive manner promotes pancreatic cancer metastasis

Oncotarget. 2017 Jan 31;8(5):7691-7709. doi: 10.18632/oncotarget.13845.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive type of pancreatic cancer with clinical characteristics of local invasion and early metastasis. Recent cohort studies indicate high fructose intake is associated with an increase in pancreatic cancer risk. However, the mechanisms by which fructose promotes pancreatic tumorigenesis remain unclear. Herein, Kras+/LSLG12D mice were crossed with Elas-CreER transgenic mice to determine whether fructose intake directly contributes to tumor formation. Orthotopic tumor-xenograft experiments were performed to determine whether fructose substitution enhances the metastatic potential of PDAC cells. The mechanisms underlying the effects of fructose were explored by RNAseq analysis in combination with high-performance anion exchange chromatography. Dietary fructose was initially found to promote the development of aggressive pancreatic cancer in mice conditionally expressing KrasG12D in the adult pancreas. We further revealed that fructose substitution enhanced the metastatic potential of human PDAC cell via selective outgrowth of aggressive ABCG2-positive subpopulations and elevating N-acetylmannosamine levels that upregulated β-galactoside α2,6-sialyltransferase 1 (ST6Gal1), thereby promoting distant metastasis. Finally, we observed that PDAC patients expressing higher levels of ST6Gal1 and GLUT5 presented poorer prognosis compared to other groups. In conclusion, our findings have elucidated a crucial role of ST6Gal1 in regulating the invasiveness of PDACs in a fructose-responsive manner.

Keywords: 6-sialyltransferase 1; fructose; metastasis; pancreatic ductal adenocarcinoma; β-galactoside α2.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily G, Member 2 / metabolism
  • Aged
  • Animals
  • Antigens, CD / genetics
  • Antigens, CD / metabolism*
  • Antineoplastic Agents / pharmacology
  • Carcinoma, Pancreatic Ductal / drug therapy
  • Carcinoma, Pancreatic Ductal / enzymology*
  • Carcinoma, Pancreatic Ductal / genetics
  • Carcinoma, Pancreatic Ductal / secondary
  • Cell Line, Tumor
  • Cell Movement / drug effects*
  • Dietary Sugars / toxicity*
  • Dose-Response Relationship, Drug
  • Female
  • Fructose / toxicity*
  • Gene Expression Regulation, Enzymologic
  • Gene Expression Regulation, Neoplastic
  • Genes, ras
  • Glucose Transporter Type 5 / metabolism
  • Hexosamines / metabolism
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Mice, Inbred NOD
  • Mice, SCID
  • Mice, Transgenic
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Proteins / metabolism
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / enzymology*
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / pathology
  • Prognosis
  • RNA Interference
  • Sialyltransferases / genetics
  • Sialyltransferases / metabolism*
  • Time Factors
  • Transfection
  • Up-Regulation

Substances

  • ABCG2 protein, human
  • ATP Binding Cassette Transporter, Subfamily G, Member 2
  • Antigens, CD
  • Antineoplastic Agents
  • Dietary Sugars
  • Glucose Transporter Type 5
  • Hexosamines
  • Neoplasm Proteins
  • SLC2A5 protein, human
  • Fructose
  • Sialyltransferases
  • ST6GAL1 protein, human
  • N-acetylmannosamine